Evidence map›Paper›PMID 30701487›Full record

ArticleCEN case reports2019

A case of apolipoprotein E Toyonaka and homozygous apolipoprotein E2/2 showing non-immune membranous nephropathy-like glomerular lesions with foamy changes.

Tamayo Kato, Yasuyuki Ushiogi, Hitoshi Yokoyama, Shigeo Hara, Akira Matsunaga, Eri Muso, Takao Saito

Abstract readCase Reports
In one paragraph

Article in CEN case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Apolipoprotein E and Atherosclerosis.Current atherosclerosis reports · 2021
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tamayo KatoDepartment of Nephrology, Fukuiken Saiseikai Hospital, 7-1 Funabashi, Wadanakacho, Fukui, 918-8503, Japan. kato.tamayo4005@fukui.saiseikai.or.jp.ORCID 0000-0001-9254-7457
Yasuyuki UshiogiDepartment of Nephrology, Fukuiken Saiseikai Hospital, 7-1 Funabashi, Wadanakacho, Fukui, 918-8503, Japan.
Hitoshi YokoyamaDepartment of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan.
Shigeo HaraDepartment of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan.
Akira MatsunagaDepartment of Laboratory Medicine, Fukuoka University School of Medicine, Fukuoka, Japan.
Eri MusoDivision of Nephrology and Dialysis, Kitano Hospital, Tazuke Kofukai Medical Institute, Osaka, Japan.
Takao SaitoSanko Clinic, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 47-year-old Japanese man with mild proteinuria was treated with an ACE inhibitor and antiplatelet agent for 7 years. However, urinary protein levels increased and renal biopsy was performed. Eight out of 20 glomeruli showed global or segmental sclerosis with foamy changes or bubbles, but with a different appearance to typical foam cells or lipoprotein thrombi. "Spike" formation, as observed in membranous nephropathy (MN), was segmentally detected in methenamine silver-stained sections. In an immunofluorescence study, weak linear patterns for IgG and scanty deposits for C3 were observed in glomeruli, but were not specific for immunogenetic MN. An electron microscopy study showed highly dense deposits in the subepithelial, subendothelial, and mesangial areas, in which microbubbles appeared under a higher magnification. Since this case exhibited hypertriglyceridemia and cholesterolemia with high serum apolipoprotein E (apoE) clinically and homozygous apoE2/2 by apoE phenotype and genotype analyses, apoE2 homozygote glomerulopathy was diagnosed and various lipid-lowering agents, e.g., probucol, fenofibrate, and ezetimibe, were administered. However, renal dysfunction gradually developed and peritoneal dialysis was initiated 11 years after the diagnosis. ApoE Toyonaka (Ser197Cys) and homozygous E2/2 were recently identified by direct DNA sequencing. Therefore, non-immune MN-like lesions may develop with the combination of these apoE mutations.

Indexed as

Apolipoprotein E2ApolipoproteinsApolipoproteins EGlomerulonephritis, MembranousHomozygoteHumansKidney DiseasesKidney GlomerulusMaleMiddle AgedMutationPeritoneal DialysisProteinuriaSequence Analysis, DNAApolipoprotein E2ApolipoproteinsApolipoproteins EApo E2 homozygote glomerulopathyApolipoprotein E ToyonakaHomozygous apolipoprotein E2/2Lipoprotein glomerulopathyMembranous nephropathy

Identifiers

PMID30701487
PMCPMC6450992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.